Verona Pharma Plc has reported further positive data for its drug ensifentrine for patients with chronic obstructive pulmonary disease (COPD). In a Phase 2 trial of patients with moderate to severe disease, the drug achieved a statistically significant and clinically meaningful increase in lung function compared with a placebo. The trial was evaluating ensifentrine in a pressurised metered-dose inhaler formulation.
